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Abstract: Cyanobacteria of the genus Lyngbya have proven to be prodigious producers of 
secondary metabolites. Many of these compounds are bioactive and show potential for 
therapeutic use. This review covers peptides and hybrid polyketide-non-ribosomal peptides 
isolated from Lyngbya species. The structures and bioactivities of 50 Lyngbya peptides 
which were reported since 2007 are presented. 
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1. Introduction 
Cyanobacteria, also called blue-green algae, are ancient aquatic and photosynthetic prokaryotes. 
The oldest known fossils of cyanobacteria come from Archaean rocks of Western Australia, dated at 
3.5 billion years [1]. Over 300 nitrogen-containing secondary metabolites from marine cyanobacteria 
have been reported in the literature [2]. It is possible that the ability to produce a wide range of 
defensive secondary metabolites has contributed to the high degree biological adaptation observed for 
cyanobacteria [3–6]. These secondary metabolites often enable cyanobacteria to compete effectively in 
a variety of environments, and many have been presented as lead compounds for further drug 
development. For instance, the synthetic analog cryptophycin 52 (1), which progressed to Phase II 
clinical trials for the treatment of patients with platinum-resistant ovarian cancer, is based on the 
cryptophycin 1 (2) which was isolated from terrestrial cyanobacteria [7,8]. Phase II clinical trials of 
dolastatin 10 failed to show significant anticancer activity. However, in vitro studies of soblidotin (or 
TZT-1027, auristatin PE) (4) a synthetic analog of dolastatin 10 (3), showed promising results against 
human colon adenocarcinomas and has progressed to phase II clinical trials [9,10]. Synthadotin (or 
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ILX-651) (6), derived from dolastatin 15 (5) showed promising results in phase II clinical trials of 
inoperable, locally advanced or metastatic melanoma [9,11]. 
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Cyanobacteria of toxicological or pharmacological significance include the genera Anabaena, 
Oscillatoria, Microcystis, Nodularia, Cylindrospermopsis and Lyngbya. Lyngbya sp. and Microcystis 
sp. are easily collected and cultured in the laboratory so that the isolation of compounds in the mg 
range is possible [12]. Lyngbya is a common and accessible genus of cyanobacteria, which is 
distributed worldwide throughout tropical and subtropical regions. The unbranched filaments of 
Lyngbya are cylindrical and usually wider than 6 µm. The straight, slightly wavy, or rarely coiled 
Lyngbya filaments usually form large, layered, leathery mats of varied thickness, and then form large 
benthic or surface blooms in freshwater and sea water. There are an increasing number of Lyngbya 
species which have been found to produce an impressive array of structurally varied compounds with 
diverse biological activities [4]. To date, the most important species of genus Lyngbya in terms of 
secondary metabolite production are L. majuscula, L. martensiana, L. aestuarii and L. wollei. Peptides 
or peptide containing substructures comprise a major group of cyanobacterial secondary metabolites. Mar. Drugs 2010, 8  
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Many of these compounds were reviewed in 2006 [2]. This review covers new peptides reported from 
Lyngbya species after 2006, with an emphasis on their structures and biological activities. However, 
conflicting taxonomic identification of cyanobacteria, including the genus Lyngbya, is common [13]. 
In most instances, the taxonomic identification was made on the basis of morphological features. Less 
frequently, identification is made on the basis of rRNA gene sequences. Even when sequence data is 
available, existing databases are often not adequate for definitive identification even at the genus level. 
The majority of biological activities reported for the compounds fall into two major categories: 
cytotoxicity or protease inhibition. 
2. Acyclic Peptides 
Six analogs of dragonamide A (7) [14], including carmabin A (8), dragomabin (9) and dragonamide 
B (10) [15], dragonamides C–D (11–12) [16] and E (13) [17], were isolated from the marine 
cyanobacteria Lyngbya majuscula and Lyngbya polychroa. This series possesses an 8 or 10-carbon 
long terminal alkynamide. To the best of our knowledge, carmabin A (8), dragomabin (9), and 
dragonamide A (7) were the only Lyngbya metabolites showing good antimalarial activity (IC50 = 4.3, 
6.0, and 7.7 μM, respectively). Dragonamides A (7) and E (13) were also antileishmanial against 
Leishmania donovani with IC50 values of 6.5 and 5.1 μM. However, the nonaromatic analog, 
dragonamide B (10), was inactive against malaria or leishmaniasis. The lack of activity for 
dragonamide B (10) suggests that an aromatic amino acid at the carboxy terminus is necessary for 
antiparasitic activity in this series. Carmabin A (8) was more cytotoxic to Vero cells (IC50 = 9.8 µM) 
than dragomabin (5) (IC50 = 182.3 µM) or dragonamide A (7) (IC50 = 67.8 µM). Thus, dragomabin (9) 
possesses the best differential toxicity between parasite and mammalian cells. It appears that the longer 
and more branched alkynamide chain of carmabin A (8) leads to the increase in cytotoxicity over that 
of dragomabin (9). Dragonamides C–D (11–12) showed weak activity in cancer cell viability assays, 
with the 50% growth inhibition (GI50) values of 56 and 59 µM against U2OS osteosarcoma cells, 22 
and 32 µM against HT29 colon adenocarcinoma cells, and 49 and 51 µM against IMR-32 
neuroblastoma cells, respectively. These data are similar to cytotoxicity data reported for 
dragonamides A (7) and B (10) against other cell lines. The antiparasitic activity of dragonamides C–D 
(11–12) was not reported. 
Screening of marine cyanobacteria from the Caribbean coast of Panama led to the identification of 
two antileishmanial lipopeptides, almiramides B–C (15–16) and their non-active analog, almiramide A 
(14) from Lyngbya majuscula [18]. Compared with the most closely related secondary metabolite 
dragonamide A (7), almiramides B–C (15–16) with an extra Ala residue, no methyl group on Val1 and 
the opposite configuration of the α-carbon of the lipophilic side chain, showed better antileishmanial 
potencies (IC50 = 2.4, and 1.9 μM, respectively), but no antimalarial activity up to 13.5 μM. The lack 
of antileishmanial activity for almiramide A (14) indicated that an unsaturated terminus on the 
lipophilic side chain played a critical role for antileishmanial activity in dragonamides and 
almiramides. Screening of a synthetic library of almiramide analogs with various modifications at the 
C- or N-terminus afforded several compounds with similar antileishmanial activity but   
improved selectivity.  
 Mar. Drugs 2010, 8  
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Name          R    
Almiramide A (14)      CH3CO- 
Almiramide B (15)      CH≡C- 
Almiramide C (16)      CH2=CH- 
Efforts toward finding marine cyanobacterial metabolites with antitumor activity led to the isolation 
of bisebromoamide (17) from a Lyngbya sp. harvested in Okinawa Prefecture [19]. Bisebromoamide 
(17) is featured by four unusual structural units, the 2-substituted thiazoline-4-methyl-4-carboxylic 
acid unit fused to a methyl-proline, 2-(1-oxopropyl) pyrrolidine (Opp) residue, N-methyl-bromo-
tyrosine and N-pivalamide moiety. Prior to the isolation of bisebromoamide (17), the Opp unit in had 
not been observed in any natural product. Bisebromoamide (17) showed cytotoxicity against HeLa S3 
cells (IC50 = 0.04 μg/mL) and a panel of 39 human cancer cell lines (termed JFCR39) (the average 
GI50 = 40 nM). At 10 to 0.1 μM, bisebromoamide (17) selectively inhibited the phosphorylation of 
ERK (extracellular signal regulated protein kinase) in NRK (normal rat kidney) cells by PDGF 
(platelet-derived growth factor)-stimulation. However PKB (protein kinase B), PKD (protein kinase Mar. Drugs 2010, 8  
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D), PLCγ1 (phospholipase Cγ1), or S6 ribosomal protein was not affected by bisebromoamide (17) at 
the same concentration range. Bisebromoamide (17) did not affect tubulin acylation as other tubulin 
modulators. It is possible that bisebromoamide (17) targets the ERK signal pathway which is activated 
in various cancers. Therefore, bisebromoamide (17) has potential as a lead for anticancer drugs.  
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Grassystatin C (20) 
Three statine unit (γ-amino-β-hydroxyacid)-containing linear peptides, termed grassystatins A–C 
(18–20), have been isolated from the marine cyanobacteria Lyngbya confervoides collected off Grassy 
Key in Florida [20]. Grassystatins A and B (18–19) showed similar potency and selectivity against 
cathepsin D (IC50 values of 26.5 nM and 7.27 nM, respectively) and E (IC50 values of 886 pM and  
354 pM, respectively). The increased affinity for cathepsin E over cathepsin D may be interpreted by 
the interaction of the polar asparagine residue in grassystatins A and B (18–19) with glutamine-303 in 
cathepsin E, which corresponds to the nonpolar residue methionine-307 in cathepsin D. Grassystatin A 
(15) was observed to reduce antigen presentation by dendritic cells, a process thought to rely on 
cathepsin E. The truncated peptide analog grassystatin C (20), which consists of two fewer residues 
than grassystatins A and B (18–19), was less potent against both cathepsins D and E, but still selective 
for cathepsin E. The selectivity of grassystatins A–C (18–20) for cathepsin E over D (20–38-fold) 
suggests that these natural products may be useful tools to probe cathepsin E function. In addition, Mar. Drugs 2010, 8  
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grassystatins A–C (18–20) were effective inhibitors of the metalloprotease TACE (tumor necrosis 
factor α−converting enzyme) with IC50s of 1.23 μM, 2.23 μM and 28.6 μM respectively. 
3. Cyclic Peptides 
An assay-based screening program for new neuroactive compounds from cyanobacteria led to the 
discovery of alotamide A (21) [21]. Alotamide A (21) is a cyclic depsipeptide featuring three 
contiguous peptidic residues linked by a polyunsaturated dihydroxyheptaketide which has not been 
found in any other natural product. Alotamide A (21) displays an unusual calcium influx activation 
profile in murine cerebrocortical neurons with an EC50 of 4.18 μM. Although the molecular target and 
mechanism for the bioactivity of alotamide A (21) is still unclear, alotamide A (21) will attract 
considerable attention to further study of this new type of cyanobacterial neurotoxin. 
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Name                R1        R2   R3   R4   
Apratoxin A (22)   Me    Me    Me    Me  
Apratoxin B (23)    H    Me    Me    Me  
Apratoxin C (24)    Me    H   Me   Me 
Apratoxin D (25)    Me    Me   H   (CH3)3CCH2- 
Apratoxin D (25) was isolated from a Papua New Guinea derived strains of the marine 
cyanobacteria Lyngbya majuscula and Lyngbya sordida [22]. Apratoxin D (25) contains the same 
macrocycle as apratoxins A–C (22–24) but possesses the unprecedented 3,7-dihydroxy-2,5,8,10,10-
pentamethylundecanoic acid as the polyketide moiety. Apratoxin D (25) showed potent in vitro 
cytotoxicity against H-460 human lung cancer cells with an IC50 value of 2.6 nM, which is nearly 
equal in potency to that of apratoxin A (22). The similar cytotoxicity of apratoxin A (22) and apratoxin 
D (25) indicates that the cytotoxicity of apratoxins is not strongly impacted by the larger lipopeptide 
tail. The isolation of apratoxin D (25) from two distinct species of the genus Lyngbya supports the 
hypothesis of genetic transfer of natural product biosynthetic pathways between marine   
cyanobacteria [23].  
A collection of the marine cyanobacterium Lyngbya bouillonii from Guam afforded the cytotoxic 
apratoxin E (26) [24]. Apratoxin E (26) displayed stronger cytotoxicity than its closest analog, 
semisynthetic E-dehydroapratoxin A (27) against several cancer cell lines derived from colon, cervix, 
and bone, ranging from 21 to 72 nM, yet is 5- to 15-fold less active than apratoxin A (22). It was 
speculated that the conformational alteration to apratoxin E (26), which results from the dehydration in 
the polyketide chain, reduces its activity. Mar. Drugs 2010, 8  
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The marine Lyngbya majuscula from Pulau Hantu Besar, Singapore afforded a cyclodepsipeptide, 
hantupeptins A–C (28–30) [25,26]. Hantupeptin A (28), B (29) and C (30) all showed 100% brine 
shrimp mortality at 100 and 10 ppm. This was significantly higher than the activity reported for their 
closest analog trungapeptin A (31), which was only mildly toxic to brine shrimp [27]. Furthermore, in 
vitro cytotoxicity testing of hantupeptins A (28), B (29) and C (30) against the leukemia cell line 
MOLT-4, displayed IC50 values of 32 nM, 0.2 μM and 3.0 μM, respectively and 4.0 μM, 0.5 μM and 
1.0 μM, respectively, against the breast cancer cell line MCF-7. In comparison, trungapeptin A (31), 
was reported to be inactive when tested at 10 μg/mL against KB or LoVo cells. It may be noteworthy 
to add that the hantupeptins have the 2R, 3S absolute configurations while the corresponding 
stereocenters in trungapeptin are 2S, 3R. 
The marine Lyngbya majuscula collected from Palmyra Atoll produced palmyramide A (32), an 
unusual cyclic depsipeptide composed of three amino acids and three hydroxy acids [28]. The   
2,2-dimethyl-3-hydroxyhexanoic acid unit (Dmhha) was also found in guineamide F (33) [29]. 
Palmyramide A (32) blocked the voltage gated sodium channel in neuro-2a cells (IC50 = 17.2 μM) and 
showed mild cytotoxicity against H-460 human lung carcinoma cells (IC50 = 39.7 μM). However, the 
cytotoxicity of guineamide F (33) was not reported. The planar structure of the 2,2-dimethyl-3-
hydroxy-7-octynoic acid unit-containing dudawalamide A (34) was recently reported [30]. In an 
interesting correlation to the acyclic dragonamide A (7) and almiramides, it also exhibited anti-
parasitic activity [31].  Mar. Drugs 2010, 8  
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Grassypeptolide (35)          L i s s o c l i n a m i d e   7   ( 36) 
A collection of the cyanobacterium Lyngbya confervoides from the Florida Keys yielded 
grassypeptolide (35), a macrocyclic depsipeptide with an unusually high D-amino acid content, two 
thiazolines, and one β-amino acid [32]. Grassypeptolide (35) inhibited four cancer cell lines derived 
from human osteosarcoma (U2OS), cervical carcinoma (HeLa), colorectal adenocarcinoma (HT29), 
and neuroblastoma (IMR-32) with IC50 values from 1.0 to 4.2 µM. These data are within the range of 
IC50 values reported for lissoclinamide 7 (36) (53.7 nM to 21.5 µM), but in different cell lines [33,34]. 
Lissoclinamide 7 (36), the most cytotoxic of the lissoclinamide series, has two thiazoline rings with the 
same arrangement and stereoconfiguration as 35. It has been shown that the thiazolines of 36  are 
important to its cytotoxic activity [34]. If this is the case, then it is very possible that grassypeptolide 
(35) and lissoclinamide 7 (36) share a similar mechanism of action. 
A cyclodepsipeptide, termed carriebowmide (37) was isolated from the lipophilic EtOAc-MeOH-
soluble fraction of Lyngbya polychroa collected from Carrie Bow Cay, Belize [35]. Carriebowmide 
(37) was also isolated from the same strain of Lyngbya majuscula that produced two depsipeptides, 
itralamides A and B (53–54) [41]. Carriebowmide (37) contains two rare amino acids, 3-amino-2-
methylhexanoic acid and methionine sulfoxide. The lipophilic EtOAc-MeOH-soluble fraction from 
Lyngbya polychroa significantly deterred feeding by a natural assemblage of reef fish. This is 
presumably due to the presence of carriebowmide (37), however the effectiveness of the purified 
compound as a feeding deterrent was not determined.  Mar. Drugs 2010, 8  
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Carriebowmide (37)         H o i a m i d e   A   ( 38) 
A combination of 
1H NMR and bioassay-guided screening for neuroactive compounds from 
cyanobacteria led to the discovery of hoiamide A (38), a bioactive cyclic depsipeptide [36]. The 15 
carbon subunit (C30 to C44) appears to be derived from a polyketide pathway. The pattern of 
oxidation and placement of pendant methyl groups suggests that the eleven-carbon main chain of 
Dmetua (5,7-dihydroxy-3-methoxy-4,6,8-trimethylundecanoic acid) may arise from the condensation 
of four propionates and one acetate unit. Hoiamide A (38) acted as a partial agonist at site 2 of the 
voltage-gate sodium channel α subunit, inhibited batrachotoxin-induced elevation of [Na
+]I  in a 
concentration dependant manner, and exhibited modest cytotoxicity to cancer cells. 
N
N
H
N
N
N
N
H
N
H
O
H
N
O
O R2
R4
O
O
O
OO
O
O
R3
R1
O
12
 
N a m e          R 1 R 2 R 3 R 4   
Desmethoxymajusculamide C (12S)    (39)   H   H   H   (S) sec-Bu 
Lyngbyastatin 3 (12R/S)      (40)   Me   Me   OMe   i-Bu 
Dolastatin 12 (12R/S)      (41)   H  Me   H   i-Bu 
Lyngbyastatin 1 (12R/S)       (42)   H   Me   OMe   i-Bu 
Majusculamide C (12S)      (43)   H   H   OMe   (S) sec-Bu 
Desmethoxymajusculamide C (39) was isolated from Lyngbya majuscula collected in Fiji [37]. The 
closely related compounds, lyngbyastatin 3 (40), dolastatin 12 (41) and lyngbyastatin 1 (42), were 
determined to be mixtures of Ibu (4-amino-2,2-dimethyl-3-oxopentanoic acid units) epimers [R 
(major) and S (minor)] whereas the structurally related majusculamide C (43) is a single diastereomer 
with an S-Ibu unit. For 40–42, but not 43, significant NMR line broadening was observed. This was Mar. Drugs 2010, 8  
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attributed to two factors: the presence of epimers and differing ratios of cis/trans conformers for 
individual epimers. Like majusculamide C (43) NMR line broadening was not observed for 39, 
suggesting the presence of a single Ibu epimer. Desmethoxymajusculamide C (39) and its ring-opened 
form (generated by breaking the ester bond) demonstrated equivalent efficacy and solid tumor 
selectivity against four cell lines, including HCT-116, H-460, MDA-MB-435 and Neuro-2A. HCT-116 
was the most sensitive cell line, with IC50 values of 20 and 16 nM, for 39 and its ring-open analog, 
respectively. This finding was discordant with the common viewpoint that the cyclic form is the 
bioactive form of the many peptides.  
4. Cyclic Peptides with One or More Amide or Ester Branches 
Tiglicamides A–C (44–46) were isolated from the Florida marine Lyngbya confervoides along with 
largamides A–C (47–49) [38,39]. The largamides and tiglicamides differ by only a single amino acid 
residue in the cyclic core. This single amino acid difference may result from assembly by an NRPS 
with adenylation domains having unusually relaxed specificity [40] or by a separate biosynthetic 
pathway. Both the largamides A–C (47–49) and the tiglicamides A–C (44–46) are serine protease 
inhibitors with selectivity for elastase over chymotrypsin and trypsin (Table 1). The carboxylic acid 
residue has little effect on the elastase inhibitory activity because the semi-synthetic largamide methyl 
esters 50–52 retained low-micromolar inhibitory activity.  
Table 1. Inhibition of serine proteases by peptides from the cyanobacterial genus Lyngbya (IC50, µM). 
Name Elastase  Chymotrypsin  Trypsin  Reference 
Tiglicamide A (44) 2.14  >50  >50  [38] 
Tiglicamide B (45) 6.99  >50  >50  [38] 
Tiglicamide C (46) 7.28  >50  >50  [38] 
Largamide A (47) 1.41  >50  >50  [39] 
Largamide B (48) 0.53  >50  >50  [39] 
Largamide C (49) 1.15  >50  >50  [39] 
Pompanopeptin A (55) 2.4     [42] 
Lyngbyastatin 4 (59)  0.0139 or 0.03  4.3 or 0.3  >30  [44,45] 
Lyngbyastatin 5 (60) 0.0032 2.8  >30  [45] 
Lyngbyastatin 6 (61) 0.0033 2.5  >30  [45] 
Lyngbyastatin 8 (62)  0.0083 or 0.047  2.5  >30  [45,46] 
Lyngbyastatin 9 (63) 0.123  /  /  [46] 
Lyngbyastatin 10 (64) 0.210  /  /  [46] 
Lyngbyastatin 7 (65) 0.120  /  /  [46] 
Somamide B (66) 0.0095  4.2  >30  [47] 
Kempopeptin A (67) 0.32 2.6  >67  [48] 
Kempopeptin B (68) >67 >67  8.4  [48] 
Scyptolin A (69)   2.8  /  >446  [50] Mar. Drugs 2010, 8  
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Name       R1   R 2 
Tiglicamide A     (44)   4-OH-PhC2H4- H 
Tiglicamide B     (45)   PhCH2-   H 
Tiglicamide C     (46)   CH3-SO-C2H4- H 
Largamide A     (47)   i-Bu   H 
Largamide B     (48)   4-OH-PhC3H6-   H 
Largamide C     (49)   4-OH-PhC4H8- H 
Largamide A methyl ester   (50)   i-Bu   Me 
Largamide B methyl ester   (51)   4-OH-PhC3H6- Me 
Largamide C methyl ester   (52)   4-OH-PhC4H8- Me 
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Name                                R1       R2            R3
Itralamide A (53)             Me     Me       i-Pr
Itralamide B (54)              i-Pr    i-Pr       Me 
 
An eastern Caribbean collection of Lyngbya majuscula produced two depsipeptides, itralamides A 
and B (53–54) [41]. Itralamide B (54) displayed significant cytotoxicity in human embryonic kidney 
(HEK-293) cells (IC50 = 6 ± 1 μM). The closely related itralamide A (53) had a ten-fold lower potency 
than itralamide B (54). The difference in the cytotoxicity of itralamides A and B (53–54) demonstrates 
that biological activities can be dramatically altered by minor modifications of structure.  
The investigation of the marine cyanobacterium Lyngbya confervoides collected from the 
southeastern coast of Florida led to the isolation of 3-amino-6-hydroxy-2-piperidone (Ahp) containing 
peptolide, pompanopeptin A (55), and a novel cyclic pentapeptide, pompanopeptin B (56) [42]. 
Pompanopeptin B (56) contains N-methyl-2-amino-6-(4’-hydroxyphenyl) hexanoic acid   
(N-Me-Ahpha) and is structurally related to carboxypeptidase-A inhibitors anabaenopeptins I (57) and 
J (58) which were isolated from the cyanobacterium Aphanizomenon flos-aquae.  The  L-Htyr and   Mar. Drugs 2010, 8  
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N-methyl-L-Ahpha, respectively in pompanopeptin B (56) were replaced by L-leucine/L-phenylalanine 
and N-methyl-L-alanine residues of 57 and 58 [43]. Pompanopeptin A (55) selectively inhibited trypsin 
over elastase and chymotrypsin, with an IC50 value of 2.4 µM (Table 1). The authors concluded that 
this selectivity is conferred by the arginine residue in the cyclic core. No activity data for 56  
is reported. 
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Lyngbyastatin 4   (59)   H   H   4-OH-PhC2H4- HO3SO-CH2-CH(OH)- 
Lyngbyastatin 5   (60)   H   H   4-OH-PhC2H4- HO-CH2-CH(OH)- 
Lyngbyastatin 6   (61)   H   Me   4-OH-PhC2H4- NaO3SO-CH2-CH(OH)- 
Lyngbyastatin 8   (62)   H   H   i-Pr        Me 
Lyngbyastatin 9   (63)   H   H   i-Pr        Pr 
Lyngbyastatin 10   (64)   Br   H   i-Pr        Pr 
Several additional members of the Ahp (3-amino-6-hyroxy-piperidone) or Amp (3-amino-6-
methoxy-piperidone) containing class of depsipeptides have been isolated and characterized from 
various species of Lyngbya. Lyngbyastatins 4–6 (59–61), were isolated from the marine 
cyanobacterium, Lyngbya confervoides which was collected off the Florida Atlantic coast [44,45]. 
Lyngbyastatins 8–10 (62–64) were isolated from the marine cyanobacterium Lyngbya semiplena, 
which was collected in Tumon Bay, Guam [46]. A Lyngbya sp., which was collected from a mangrove Mar. Drugs 2010, 8  
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channel at Summerland Key in Florida, provided lyngbyastatin 7 (65) [45], somamide B (66) [47] and 
kempopeptins A and B (67–68) [48]. This class of compounds inhibits serine proteases, although the 
group exhibits a wide range of potency and varied selectivity (Table 1). When compared to the 
inhibitory activity of tiglicamides A-C (44–46), the Ahp containing depsipeptides are two to three 
orders of magnitudes more effective against porcine pancreatic elastase in vitro (Table 1). Like the 
tiglicamides (44–46) and the largamides (47–49), the Ahp containing serine proteases retain selectivity 
for elastase over chymostrysin or trypsin. Extensive structure activity studies as well as the crystal 
structures of the related desipeptide scyptolin A (69) bound to elastase [49,50] and cyanopeptolin 
A90720A bound to trypsin [51], revealed important interactions in the enzyme binding site and 
provided critical insights into the selectivity of this class of inhibitors. In the co-crystal structure of 
scyptolin-elastase, the threonine residue that forms ester bond occupies the S2 subsite of the protease. 
The valine which is C-terminal to this threonine binds the S1 subsite of the protease. The threonine 
and alanine of the pendant side-chain, bind subunits S3 and S4. The relative potencies of these new 
depsipeptides are consistent with earlier studies. Hydrophobic residues between the Thr that forms the 
ester bond of the depsipeptide and the Ahp residue impart selectivity for elastase as exemplified by the 
lynbyastatins (Abu), kempopeptin A (leucine) and scyptolin A (valine), whereas a basic residue at this 
position imparts selectivity for trypsin exemplified by kempopeptin B (lysine in 68) and 
pompanopeptin A (argenine in 55). In comparison with lynbyastatin 7 (65), lyngbyastatins 8–10   
(62–64) exhibited weaker inhibition against porcine pancreatic elastase. Lyngbyastatins 8–10 (62–64) 
and lynbyastatin 7 (65) share the same depsipeptide core. Therefore, the reduced potency may be 
attributed to differences in the side chain residues. The exclusively hydrophobic residues in the 
pendant chain may form more favorable electrostatic interactions and hydrogen bonding with the 
enzyme. The fact that the protease-inhibitory activity is retained in the O-methylated (Amp) derivative, 
lyngbyastatin 6 (60), demonstrates that the hydroxyl group in the Ahp unit is not critical for the 
inhibition of elastase or chymotrypsin. 
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Pahayokolides A–B (70–71), lyngbyazothrins A–D (72–75) and schizotrin A (76) are remarkably 
similar in structure. Pahayokolides A–B (70–71) and lyngbyazothrins A–D (72–75) were produced by 
a freshwater Lyngbya sp. isolated from the Florida Everglades and the cultured Lyngbya sp. 36.91 
SAG collected from Göttingen, Germany respectively [52–54]. On the other hand schizotrin A (76) 
and the tychonamides (77–78) were isolated from Schizotrix sp. [55] and Tchyonema sp. [56] 
respectively. Each of these cyclic undecapeptides contains the sequence (Val/Ile/Dhb)-Ser-Dhb-
(Ser/Thr)-(homo-Phe/homo-Tyr)-Pro-X-Gln-Gly-Pro-(Pro/Phe), where X is an unusual, long-chain 
α,γ-hydroxy-β- amino acid. In the pahayokolides (70–71), the lyngbyazothrins (72–75) and schizotrin 
A (76) the α,γ-hydroxy-β-amino acid is 3-amino-2,5,7,8-tetrahydroxy-10-methylundecanoic acid 
(Athmu) and in tychonamides (77–78) it is a 3-amino-2,5,7,-trihydroxy-8-phenyloctanoic acid moiety 
(Atpoa). The γ-hydroxy group may or may not be decorated through an ester linkage to an N-acetyl-N-
methyl leucine (pahayokolides and tychonamides) an N-butyroyl-N-methyl alanine (schizotrin A) or an 
N-acetyl-N-methyl tyrosine (lyngbyazothrins). To the best of our knowledge, these two long-chain  
α,γ-hydroxy-β-amino acids have not been observed elsewhere. It may be noteworthy that the 
pahayokolides, schizotrin, the lynbyazothrins and tychonamides, which are remarkably similar in 
structure, were all isolated from freshwater species. Pahayokolide A (70) inhibits a number of cancer 
cell lines over a range of concentrations (IC50 varied from 2.13 to 44.57 μM), is acutely toxic to 
zebrafish embryos (LC50 = 2.15 μM), and only marginally toxic against brine shrimp at the highest 
concentrations tested (1 mg/mL) [57]. The mixture of lyngbyazothrins A (72) and B (73) showed only 
low antimicrobial activity against Micrococcus flavus, whereas the mixture of lyngbyazothrins C (74) 
and D (75) was active against Bacillus subtilis,  Escherichia coli,  Pseudomonas aeruginosa, and 
Serratia marcescens. It seems that the acyl residue at C-5 of Athmu plays an important role in 
antimicrobial activity. This assumption was supported by the activity and structure of pahayokolides 
A-B (70–71). 
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Fifty new peptides isolated from Lyngbya species, reported since 2006 have been reviewed and 
their bioactivities discussed. All but six of these new compounds were derived from marine species of 
Lyngbya, although it is likely that this represents a sampling bias rather than a significant difference in 
biosynthetic capability between marine and freshwater species. The genus Lyngbya appears to be an 
emerging source of bioactive peptides. A search of Chemical Abstracts for original research articles 
using the keywords “Lyngbya” and “peptide” returns 105 citations from 1980 to the present, of which 
nearly 1/3 have been published during the time covered by this review. In a recent review, Welker 
described seven major and three minor structural classes which encompass just over 50% of all known 
cyanaobacterial peptides [12]. In contrast, only 11 of the 50 new peptides covered in this review fall 
within one of the identified classes: pompanopeptin A (55), lyngbyastatins 4–10 (59–64) and 
kempopeptins A and B (67–68) belong to the larger group of cyanopeptolins. While pompanopeptin B 
(56) falls within the anabaenopeptins. Lyngbya derived peptides share many features with other 
cyanobacterial peptides, such as N-methylation, the incorporation of D-amino acids, thiazolines or 
oxazolines and subunits of polyketide or mixed-polyketide and non-ribosomal peptide origin. 
Nonetheless, the majority of the peptides covered is unique to Lyngbya species and encompass one or 
only a few analogs. It is common for cyanobacteria, to produce more than one member of a certain 
structural class. This phenomenon is partially a result of relaxed specificity of biosynthetic enzymes 
[58]. As prokaryotic polyketide synthases (PKS) can show considerable substrate tolerance [59], so 
may adenylation domains of non-ribosomal peptide synthetase (NRPS) accept different amino acids 
within a group of polar or nonpolar residues [60]. Natural structural diversification may also be the 
result of slight genetic variation or a slightly changed environment. With the possible exception of the 
linear dragonamides and almiramides, it is likely that these peptides are made non-ribosomally. To 
date, five biosynthetic pathways for Lyngbya peptides have been identified; barbamide, curacin A, 
lyngbyatoxin, jamacamide, and hectochlorin [61–65]. These pathways serve to illustrate the 
tremendous biosynthetic diversity offered by this genus. Mar. Drugs 2010, 8  
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A number of the reviewed Lyngbya peptides, especially acyclic peptides (8–12 and 17) and cyclic 
peptides without branches (25–26, 28–30, 32, 35, 39, 53–54) exhibit cytotoxic activity against the 
various cancer cell lines. Only one cyclic Lyngbya peptide with branches, pahayokolide A inhibits a 
number of cancer cell lines over a range of concentrations. However, most of the reviewed cyclic 
branched-peptides (44–49,  55,  59–65,  67–68) inhibit proteases with a wide range of potency and 
varied selectivity. Bioactive Lyngbya peptides may be considered to be a valuable pool of lead 
compounds in structure-based drug design and discovery.  
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